-
Tim Anderson of Bernstein Research, another analyst who has been advocating a break up, asked exactly that.
FORBES: Why Pfizer Will Break Up
-
In a report last week, Tim Anderson, a sell-side analyst at Prudential Equities group, predicted that the Premarin trial would be ending early (see " Wyeth's Premarin Trial Seen Ending Early").
FORBES: Wyeth Lucks Out On Hormone Study
-
The reason to think Merck may succeed, argues Tim Anderson of Sanford Bernstein, a research firm, is that it has found a way to make biosimilars by culturing them inside yeast cells.
ECONOMIST: Pharmaceuticals